0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TrkA

TrkA

TrkA Molecule Information

Name:Nerve growth factor receptor Trk-A
Target Synonym:Neurotrophic tyrosine kinase receptor type 1;Trk-A;NTRK1;MTC ;High affinity nerve growth factor receptor;TRK1-transforming tyrosine kinase protein;Tropomyosin-related kinase A;TRKA;Tyrosine kinase receptor A;TRK;Tyrosine kinase receptor;gp140trk;p140-TrkA
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:23
Lastest Research Phase:Approved

TrkA Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TRA-H5253 Human Human TrkA / NTRK1 (192-402) Protein, Mouse IgG2a Fc Tag
TRA-H5253-structure
TRA-H5253-sds
TRA-H5259 Human Human TrkA / NTRK1 (33-417) Protein, Mouse IgG2a Fc Tag
TRA-H5259-structure
TRA-H5259-sds

TrkA Molecule Synonym Name

TrkA,NTRK1,MTC,TRK,TRKA,Trk-A

TrkA Molecule Background

Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand. Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival. Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors.

TrkA References

TrkA Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Entrectinib NMS-E628; RG-6268; RXDX-101 Approved Nerviano Medical Sciences, Ignyta Pharma, Chugai, Genentech Entrectinib 日本 Solid tumours 中外制药 2019-06-18 00:00:00.0 Solid tumours, ROS1-positive non-small cell lung cancer (NSCLC) Details
Regorafenib Monohydrate BAY-73-4506; DAST,BAY73-4506,BAY 73-4506,BAY-734506 Approved Bayer, Onyx Pharmaceutical STIVARGA fda Gastrointestinal stromal tumors (GISTs), Metastatic colorectal cancer (CRC) BAYER HLTHCARE 2012-09-27 Gastrointestinal stromal tumors (GISTs), Liver cancer, Metastatic colorectal cancer (CRC), Hepatocellular carcinoma (HCC) Details
Larotrectinib sulfate ARRY-470; LOXO-101 Approved Array BioPharma, Loxo Oncology, Bayer VITRAKVI fda Solid tumours BAYER HLTHCARE 2018-11-26 Solid tumours Details

TrkA Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Repotrectinib TPX-0005,TPX0005,TPX 0005 Phase Ⅱ Turning Point Therapeutics Non small cell lung cancer (NSCLC), Solid tumours Details
Belizatinib TSR-011,TSR011 Phase Ⅱ Amgen, Tesaro Non small cell lung cancer (NSCLC), Solid tumours, Lymphoma Details
AZD-7451 AZD-7451,AZD7451 Phase Ⅰ AstraZeneca, National Cancer Institute Glioblastoma multiforme Details
ACD-856 ACD-856 Phase Ⅰ AlzeCure Pharma AB Alzheimer's disease (AD) Details
VMD-928 VMD-928 Phase Ⅰ VM Oncology Solid tumours, Lymphoma Details
AZD-6918 AZD-6918 Phase Ⅰ AstraZeneca Solid tumours Details
FCN-011 FCN-011 Phase Ⅰ Fochon Pharmaceuticals Solid tumours Details
Nerve growth factor (Genentech) Phase Ⅲ Chiron, Amgen, Genentech, Ceregene Neuropathic pain, Diabetic neuropathy, Alzheimer's disease (AD), Herpes simplex virus (HSV) infection, Peripheral  neuropathy Details
FX-007 FX-007,FX007;FX 007 Preclinical AstraZeneca, Flexion Therapeutics Postoperative pain, Musculoskeletal pain Details
BN-201 BN-201 Phase Ⅰ Bionure Optic neuritis, Neuromyelitis optica (NMO) Details
GZ-389988 GZ-389988; GZ-389988A; GR-389988 Phase Ⅱ Sanofi Osteoarthritis (OA) Details
Altiratinib DCC-22701; DCC-2701; DP-5164; T-678746713 Phase Ⅰ Deciphera Solid tumours Details
CE-245677 CE-245677 Phase Ⅰ Pfizer Cancer Details
TQB-3558 TQB-3558 Phase Ⅰ Chiatai Tianqing (CTTQ) Advanced solid tumors Details
DS-6051 DS-6051; DS-6051a; DS-6051b; AB-106,DS6051b,DS6051a,DS6051,AB106 Phase Ⅱ Daiichi Sankyo, AnHeart Therapeutics Non small cell lung cancer (NSCLC), Solid tumours Details
GBR-900 GBR-900; hMNAC-13; MNAC-13; BXL-1H5 Phase Ⅰ Lay Line Genomics, Glenmark Pharmaceuticals Chronic pain Details
Lestaurtinib A-154475.0; CEP-701; KT-5555; SP-924; SPM-924 Phase Ⅲ Kyowa Hakko Kirin, Cephalon Acute lymphoblastic leukaemia (ALL) Details
VM-902A VM-902A; VM-902,VM902A,VM902 Phase Ⅱ VM Discovery, Purdue Pharma Pain Details
Milciclib maleate PHA-848125C; PHA-125; PHA-848125; PHA-848125AC; TZLS-201 Phase Ⅱ Nerviano Medical Sciences, Tiziana Life Sciences Thymic tumor, Liver cancer Details
HG-030 HG-030,HG030 Phase Ⅰ HitGen Solid tumours Details
AK-1830 (Array BioPharma) AK-1830 Phase Ⅰ Array BioPharma Inflammation Details
PLX-7486 PLX-7486; PLX7486-TsOH Phase Ⅱ Daiichi Sankyo Solid tumours, Pancreatic cancer Details
DBPR-114 Phase Ⅰ National Health Research Institutes Cancer Details
Pegcantratinib CT 301/P; CT 327; K-252a-PEG2K; Pegylated K252A; SNA-120 Phase Ⅱ Cephalon, Creabilis Plaque psoriasis, Atopic dermatitis Details
ASP-7962 ASP-7962,ASP7962 Phase Ⅱ Astellas Pain Details
ACD-855 ACD-855 Phase Ⅰ AlzeCure Pharma AB Alzheimer's disease (AD) Details
SNA-125 CT-340; SNA-125 Phase Ⅱ Creabilis, Sienna Biopharmaceuticals Pruritus, Psoriasis, Atopic dermatitis Details

This web search service is supported by Google Inc.

totop